Dominique Lopez

Khat use and monitoring drug use in Europe: the current situation and issues for the future.

AIM OF THE STUDY To review the information available on the use of khat (Catha edulis) in the EU, and to assess the future use of this drug and related substances. MATERIAL AND METHODS Khat is not controlled by international law and it has not been systematically included in the list of illicit drugs monitored in the EU. The current principal source of information on khat use in Europe is the early-warning system set up to monitor new and emerging drugs. Further information was obtained from official national reports to the EMCDDA and from the scientific literature. RESULTS Across Europe, the use of khat is low. Khat use is limited to countries with immigrant communities from countries where khat use is common (such as Ethiopia, Somalia and Kenya). Information on the prevalence of khat use in the general population is scarce. Data on seizures provide an insight on the situation, though these may be difficult to interpret. The most recent estimates suggest that Europe accounts for about 40% of the khat seized worldwide. CONCLUSION The shortage of data on the use and patterns of use of khat in Europe does not allow an evaluation of the needs for health and social interventions in communities in which the drug is used. But seizures of the plant are increasing in the EU, and more synthetic derivatives of the pharmacologically active ingredients of the plant (cathine and cathinone) are appearing on the market. Some of these, like mephedrone, have significant potential for future diffusion, and are likely to play a greater role on the European drug scene of the future.

Disability and Poverty in Morocco and Tunisia: A Multidimensional Approach

Abstract Although a growing body of research is exploring the links between disability and poverty, the evidence that persons with disabilities are more likely to be poor than their non-disabled counterpart remains scarce. The causal relationship between disability and poverty has most often been considered in terms of disparities in income or living conditions. However, some research strongly suggests that disability is associated with deprivation in a number of other dimensions. To date, no study has examined these associations using large scale surveys with a wide range of wellbeing dimensions and indicators using a multidimensional approach. The present paper presents findings of three multidimensional poverty measures based on 17 indicators of deprivation collected through large-scale household surveys in Morocco and Tunisia. These indicators cover a wide range of dimensions of poverty such as health, education, employment, material well-being, social participation, psychological well-being and physical security. Results confirm that persons with disabilities are poorer than non-disabled people in both countries. The study shows that persons with disabilities, particularly girls and women, rural residents, and those with intellectual, mental or multiple disabilities are particularly deprived of basic capabilities and functionings and that stigma plays a role in this social injustice. Civil society organizations should take the lead to promote awareness of social and emotional well-being of persons with disabilities.

Addiction Research Centres and the Nurturing of Creativity Monitoring the European drug situation: the ongoing challenge for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the designated hub for drug-related information in the European Union. The organizations role is to provide the European Union (EU) and its Member States with a factual overview of European drug problems and a common information framework to support the drugs debate. In order to achieve its mission, the EMCDDA coordinates and relies on a network of 30 national monitoring centres, the Reitox National Focal Points. The Centre publishes on a wide range of drug-related topics, across epidemiology, interventions, laws and policies. Every November, the EMCDDA publishes its Annual Report, providing a yearly update on the European drug situation, translated into 23 EU languages. In line with its founding regulation, the EMCDDA has a role acting as an interface between the worlds of science and policy. While not a research centre in the formal sense, the results the Centre generates serve as catalysts for new research questions and help to identify priorities. Current challenges facing the agency include continuing to increase scientific standards while maintaining a strong institutional role, as well as supporting European efforts to identify, share and codify best practice in the drugs field.